DENTSPLY SIRONA INC (XRAY) Stock Fundamental Analysis
USA - NASDAQ:XRAY - US24906P1093 - Common Stock
10.515 USD
0 (-0.05%)
XRAY gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 188 industry peers in the Health Care Equipment & Supplies industry. While XRAY is still in line with the averages on profitability rating, there are concerns on its financial health. XRAY has a bad growth rate and is valued cheaply. XRAY also has an excellent dividend rating.
1. Profitability
1.1 Basic Checks
XRAY had positive earnings in the past year.
In the past year XRAY had a positive cash flow from operations.
XRAY had negative earnings in 4 of the past 5 years.
Each year in the past 5 years XRAY had a positive operating cash flow.
1.2 Ratios
XRAY has a Return On Assets (-15.60%) which is in line with its industry peers.
The Return On Equity of XRAY (-59.68%) is comparable to the rest of the industry.
XRAY's Return On Invested Capital of 5.04% is fine compared to the rest of the industry. XRAY outperforms 77.13% of its industry peers.
XRAY had an Average Return On Invested Capital over the past 3 years of 4.11%. This is below the industry average of 8.98%.
The last Return On Invested Capital (5.04%) for XRAY is above the 3 year average (4.11%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -15.6% | ||
| ROE | -59.68% | ||
| ROIC | 5.04% |
ROA(3y)-10.01%
ROA(5y)-5.27%
ROE(3y)-25.27%
ROE(5y)-13.81%
ROIC(3y)4.11%
ROIC(5y)4.26%
1.3 Margins
With a decent Operating Margin value of 7.48%, XRAY is doing good in the industry, outperforming 73.94% of the companies in the same industry.
In the last couple of years the Operating Margin of XRAY has declined.
The Gross Margin of XRAY (51.10%) is comparable to the rest of the industry.
XRAY's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 7.48% | ||
| PM (TTM) | N/A | ||
| GM | 51.1% |
OM growth 3Y-25.8%
OM growth 5Y-12.74%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.16%
GM growth 5Y-0.95%
2. Health
2.1 Basic Checks
XRAY has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
Compared to 1 year ago, XRAY has less shares outstanding
The number of shares outstanding for XRAY has been reduced compared to 5 years ago.
Compared to 1 year ago, XRAY has a worse debt to assets ratio.
2.2 Solvency
XRAY has an Altman-Z score of 0.90. This is a bad value and indicates that XRAY is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of 0.90, XRAY perfoms like the industry average, outperforming 52.66% of the companies in the same industry.
The Debt to FCF ratio of XRAY is 29.94, which is on the high side as it means it would take XRAY, 29.94 years of fcf income to pay off all of its debts.
XRAY has a better Debt to FCF ratio (29.94) than 67.55% of its industry peers.
XRAY has a Debt/Equity ratio of 1.36. This is a high value indicating a heavy dependency on external financing.
XRAY has a worse Debt to Equity ratio (1.36) than 79.79% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.36 | ||
| Debt/FCF | 29.94 | ||
| Altman-Z | 0.9 |
ROIC/WACC0.83
WACC6.06%
2.3 Liquidity
A Current Ratio of 1.47 indicates that XRAY should not have too much problems paying its short term obligations.
XRAY has a worse Current ratio (1.47) than 77.13% of its industry peers.
XRAY has a Quick Ratio of 1.47. This is a bad value and indicates that XRAY is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.99, XRAY is not doing good in the industry: 77.66% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.47 | ||
| Quick Ratio | 0.99 |
3. Growth
3.1 Past
The earnings per share for XRAY have decreased strongly by -14.59% in the last year.
XRAY shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -7.38% yearly.
Looking at the last year, XRAY shows a decrease in Revenue. The Revenue has decreased by -7.08% in the last year.
XRAY shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -1.17% yearly.
EPS 1Y (TTM)-14.59%
EPS 3Y-16.51%
EPS 5Y-7.38%
EPS Q2Q%-26%
Revenue 1Y (TTM)-7.08%
Revenue growth 3Y-3.58%
Revenue growth 5Y-1.17%
Sales Q2Q%-4.94%
3.2 Future
The Earnings Per Share is expected to grow by 11.25% on average over the next years. This is quite good.
The Revenue is expected to grow by 2.02% on average over the next years.
EPS Next Y14.71%
EPS Next 2Y11.04%
EPS Next 3Y10.19%
EPS Next 5Y11.25%
Revenue Next Year-4.07%
Revenue Next 2Y-1.35%
Revenue Next 3Y0.15%
Revenue Next 5Y2.02%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 6.66 indicates a rather cheap valuation of XRAY.
Based on the Price/Earnings ratio, XRAY is valued cheaper than 96.81% of the companies in the same industry.
XRAY's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 25.89.
XRAY is valuated cheaply with a Price/Forward Earnings ratio of 5.11.
XRAY's Price/Forward Earnings ratio is rather cheap when compared to the industry. XRAY is cheaper than 98.40% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 34.59. XRAY is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 6.66 | ||
| Fwd PE | 5.11 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of XRAY indicates a rather cheap valuation: XRAY is cheaper than 95.21% of the companies listed in the same industry.
80.32% of the companies in the same industry are more expensive than XRAY, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 26.22 | ||
| EV/EBITDA | 6.68 |
4.3 Compensation for Growth
XRAY's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)0.45
PEG (5Y)N/A
EPS Next 2Y11.04%
EPS Next 3Y10.19%
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 4.91%, XRAY is a good candidate for dividend investing.
The stock price of XRAY dropped by -24.04% in the last 3 months. With lower prices the dividend yield is higher, but it may be a sign investors do not trust the long term dividend.
XRAY's Dividend Yield is rather good when compared to the industry average which is at 1.69. XRAY pays more dividend than 100.00% of the companies in the same industry.
XRAY's Dividend Yield is rather good when compared to the S&P500 average which is at 2.44.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.91% |
5.2 History
On average, the dividend of XRAY grows each year by 11.21%, which is quite nice.
XRAY has been paying a dividend for at least 10 years, so it has a reliable track record.
XRAY has not decreased their dividend for at least 10 years, which is a reliable track record.
Dividend Growth(5Y)11.21%
Div Incr Years6
Div Non Decr Years30
5.3 Sustainability
The earnings of XRAY are negative and hence is the payout ratio. XRAY will probably not be able to sustain this dividend level.
The dividend of XRAY is growing around the same rate as the earnings are growing. If this keeps up the dividend growth is sustainable.
DP-14.4%
EPS Next 2Y11.04%
EPS Next 3Y10.19%
NASDAQ:XRAY (11/17/2025, 12:01:43 PM)
10.515
0 (-0.05%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners104.22%
Inst Owner Change4.48%
Ins Owners0.32%
Ins Owner Change5.98%
Market Cap2.10B
Revenue(TTM)3.62B
Net Income(TTM)-882.00M
Analysts70.91
Price Target16.19 (53.97%)
Short Float %4.51%
Short Ratio2.91
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.91% |
Yearly Dividend0.62
Dividend Growth(5Y)11.21%
DP-14.4%
Div Incr Years6
Div Non Decr Years30
Ex-Date
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-8.77%
Min EPS beat(2)-19.03%
Max EPS beat(2)1.49%
EPS beat(4)2
Avg EPS beat(4)-3.17%
Min EPS beat(4)-40.52%
Max EPS beat(4)45.37%
EPS beat(8)3
Avg EPS beat(8)-1.68%
EPS beat(12)6
Avg EPS beat(12)4.59%
EPS beat(16)7
Avg EPS beat(16)1.99%
Revenue beat(2)0
Avg Revenue beat(2)-1.42%
Min Revenue beat(2)-1.67%
Max Revenue beat(2)-1.16%
Revenue beat(4)1
Avg Revenue beat(4)-1.42%
Min Revenue beat(4)-3.62%
Max Revenue beat(4)0.77%
Revenue beat(8)2
Avg Revenue beat(8)-1.44%
Revenue beat(12)5
Avg Revenue beat(12)-0.9%
Revenue beat(16)5
Avg Revenue beat(16)-2.02%
PT rev (1m)-4.51%
PT rev (3m)-12.21%
EPS NQ rev (1m)-31.93%
EPS NQ rev (3m)-32.33%
EPS NY rev (1m)-0.46%
EPS NY rev (3m)-1.01%
Revenue NQ rev (1m)-1.12%
Revenue NQ rev (3m)-0.92%
Revenue NY rev (1m)-0.05%
Revenue NY rev (3m)0.05%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 6.66 | ||
| Fwd PE | 5.11 | ||
| P/S | 0.58 | ||
| P/FCF | 26.22 | ||
| P/OCF | 9.49 | ||
| P/B | 1.42 | ||
| P/tB | N/A | ||
| EV/EBITDA | 6.68 |
EPS(TTM)1.58
EY15.03%
EPS(NY)2.06
Fwd EY19.58%
FCF(TTM)0.4
FCFY3.81%
OCF(TTM)1.11
OCFY10.54%
SpS18.17
BVpS7.41
TBVpS-4.3
PEG (NY)0.45
PEG (5Y)N/A
Graham Number16.23
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -15.6% | ||
| ROE | -59.68% | ||
| ROCE | 6.38% | ||
| ROIC | 5.04% | ||
| ROICexc | 5.51% | ||
| ROICexgc | 13.81% | ||
| OM | 7.48% | ||
| PM (TTM) | N/A | ||
| GM | 51.1% | ||
| FCFM | 2.21% |
ROA(3y)-10.01%
ROA(5y)-5.27%
ROE(3y)-25.27%
ROE(5y)-13.81%
ROIC(3y)4.11%
ROIC(5y)4.26%
ROICexc(3y)4.36%
ROICexc(5y)4.5%
ROICexgc(3y)15.64%
ROICexgc(5y)20.94%
ROCE(3y)5.38%
ROCE(5y)5.49%
ROICexgc growth 3Y-31.16%
ROICexgc growth 5Y-12.42%
ROICexc growth 3Y-13.44%
ROICexc growth 5Y-4.44%
OM growth 3Y-25.8%
OM growth 5Y-12.74%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.16%
GM growth 5Y-0.95%
F-Score4
Asset Turnover0.64
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.36 | ||
| Debt/FCF | 29.94 | ||
| Debt/EBITDA | 3.26 | ||
| Cap/Depr | 40.63% | ||
| Cap/Sales | 3.89% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 35.76% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.47 | ||
| Quick Ratio | 0.99 | ||
| Altman-Z | 0.9 |
F-Score4
WACC6.06%
ROIC/WACC0.83
Cap/Depr(3y)46.81%
Cap/Depr(5y)41.51%
Cap/Sales(3y)4.1%
Cap/Sales(5y)3.65%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-14.59%
EPS 3Y-16.51%
EPS 5Y-7.38%
EPS Q2Q%-26%
EPS Next Y14.71%
EPS Next 2Y11.04%
EPS Next 3Y10.19%
EPS Next 5Y11.25%
Revenue 1Y (TTM)-7.08%
Revenue growth 3Y-3.58%
Revenue growth 5Y-1.17%
Sales Q2Q%-4.94%
Revenue Next Year-4.07%
Revenue Next 2Y-1.35%
Revenue Next 3Y0.15%
Revenue Next 5Y2.02%
EBIT growth 1Y3.04%
EBIT growth 3Y-28.45%
EBIT growth 5Y-13.75%
EBIT Next Year53.77%
EBIT Next 3Y18.64%
EBIT Next 5Y12.9%
FCF growth 1Y-63.3%
FCF growth 3Y-18.29%
FCF growth 5Y-11.45%
OCF growth 1Y-38.44%
OCF growth 3Y-11.14%
OCF growth 5Y-6.32%
DENTSPLY SIRONA INC / XRAY FAQ
Can you provide the ChartMill fundamental rating for DENTSPLY SIRONA INC?
ChartMill assigns a fundamental rating of 4 / 10 to XRAY.
Can you provide the valuation status for DENTSPLY SIRONA INC?
ChartMill assigns a valuation rating of 8 / 10 to DENTSPLY SIRONA INC (XRAY). This can be considered as Undervalued.
How profitable is DENTSPLY SIRONA INC (XRAY) stock?
DENTSPLY SIRONA INC (XRAY) has a profitability rating of 4 / 10.
What is the valuation of DENTSPLY SIRONA INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for DENTSPLY SIRONA INC (XRAY) is 6.66 and the Price/Book (PB) ratio is 1.42.
How sustainable is the dividend of DENTSPLY SIRONA INC (XRAY) stock?
The dividend rating of DENTSPLY SIRONA INC (XRAY) is 8 / 10 and the dividend payout ratio is -14.4%.